Beeline Medicines, backed by Bristol Myers Squibb and investors including Bain Capital, added $126.3 million in an extension to its Series A after the company emerged from stealth earlier this year with five autoimmune programs and $300 million in funding. The new tranche reinforces Beeline’s “worker bee” buildout plan as it advances multiple immunology candidates. The company’s strategy leans on rapid execution across programs rather than single-asset focus, which is consistent with how autoimmune portfolios are increasingly financed and managed. The extension also provides flexibility for platform buildout, translational studies, and potential additional internal hires. For peers, the round highlights investor appetite for preclinical autoimmune pipelines that are already supported by credible industrial partners.